尼亚通过调节SIRT1/SIRT6信号通路来抑制血管化
Chao-Hua Kong1, Li-da Wu1, Yue Sun1
1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Cell death discovery
|December 6, 2025
概括
尼雅是一种维生素B3衍生物,通过保持Sirtuin 1 (SIRT1) 和Sirtuin 6 (SIRT6) 水平来降低血管化 (VC). 这项研究表明,氨酸作为治疗慢性病患者的VC治疗的潜在治疗剂.
科学领域:
- 生物医学科学 生物医学科学
- 心血管研究研究心血管研究
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 血管化 (VC) 是一种病理过程,与-不平衡和慢性病 (CKD) 有关.
- 血管光滑肌细胞 (VSMCs) 在VC的发展中起着至关重要的作用.
- 尼雅在VC中的治疗潜力以前没有被研究过.
研究的目的:
- 为了研究氨酸对血管化的作用.
- 阐明氨酸在VC中的作用的潜在分子机制.
- 探索尼亚作为潜在的治疗策略的VC.
主要方法:
- 使用受限立方脊柱 (RCS) 对临床数据集的分析,以将素摄入量与腹腔大动脉化 (AAC) 相关联.
- 实验室研究评估尼雅对VSMC骨质分化的影响.
- 使用C57BL/6J小鼠进行体内实验,以评估氨酸在CKD和维生素D3诱导的VC模型中的有效性.
- 研究尼亚对VSMC中的Sirtuin 1 (SIRT1) 和Sirtuin 6 (SIRT6) 水平和自流量的影响.
主要成果:
- 临床数据显示,饮食中素摄入量与AAC之间存在逆相关性.
- 尼亚治疗显著抑制了VSMC骨质分化.
- 在CKD和维生素D3中毒的小鼠模型中,尼亚的使用改善了VC.
- 尼雅被发现可以维持SIRT1和SIRT6水平,并增强SIRT1/SIRT6介导的自流在VSMCs.
结论:
- 尼亚在血管光滑肌肉细胞中表现出显著的抗化作用.
- 该机制涉及维持SIRT1和SIRT6水平,从而促进自.
- 尼亚为管理血管化提供了一个有前途的治疗途径,特别是在CKD的背景下.
相关概念视频
Nitric Oxide Signaling Pathway
6.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.1K
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Antihypertensive Drugs: Action of Calcium Channel Blockers
1.5K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


